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Abstract Cardiac magnetic resonance imaging (CMR) has
undergone considerable technology advances in recent years,
so that it is now entering into mainstream cardiac imaging
practice. In particular, CMR is proving to be a valuable
imaging tool in the detection, morphological assessment and
functional assessment of cardiomyopathies. Although our
understanding ofthisbroad group ofheart disorders continues
to expand, it is an evolving group of entities, with the rarer
cardiomyopathies remaining poorly understood or even
unclassified. In this review, we describe the clinical and
pathophysiological aspects of several of the rare/unclassified
cardiomyopathies and their appearance on CMR.
Keywords Humans.Magnetic resonance imaging.
Cardiomyopathies/diagnosis.Ventricular dysfunction/
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Introduction
The prevalence of cardiomyopathy in the United States is
approximately one in 5,439 or 0.02% of the population [1].
Approximately 26,000 deaths per annum are attributed to
cardiomyopathy, which follows coronary heart disease as the
commonest cause of sudden death. Transthoracic echocardi-
ography (TTE) is the mainstay imaging modality for
cardiomyopathy assessment [2]. Nevertheless, poor acoustic
windows can make it difficult to optimally assess certain
patients.
Several evolving technical developments have allowed
cardiac magnetic resonance imaging (CMR) to enter main-
stream cardiology imaging practice for cardiomyopathy
assessment [3]. Increasing magnet strengths and surface
coil channels and rapid k-space sampling have resulted in
faster scan times, placing CMR in a primary position in the
work-up of many complex cardiomyopathies [4]. Several
consensus statements include CMR as a primary imaging
technique in cardiomyopathy assessment [3, 5]. In this
review,weoutlinetheclinicalandpathophysiologicalaspects
of several of the rarer or unclassified cardiomyopathies and
their appearances on CMR.
Classification of cardiomyopathy
In 2006 a re-classification of the cardiomyopathies was
published, as our understanding of the importance of
genetics in the pathophysiology of the cardiomyopathies
became more central [6]. This consensus report revised the
definition of cardiomyopathy to include “mechanical or
electrical dysfunction that usually exhibits inappropriate
ventricular hypertrophy and dilatation due to a variety of
causes that frequently are genetic”. Under this classification
system, the division of cardiomyopathy was divided into
primary and secondary causes. A more recent classification
published by Elliott et al. [7] from the European society of
cardiology working group on myocardial and pericardial
diseases places an emphasis on phenotypic classification.
In this system, cardiomyopathies are divided into five
specific morphological and functional subgroups: hyper-
trophic, dilated, arrhythmogenic, restrictive and unclassified
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294 Insights Imaging (2010) 1:293–308(Table 1). Each of these groups is then further subdivided
into familial and non–familial forms. Each morphological
group of cardiomyopathies has common and rare forms.
Uncommon cardiomyopathies characterized by hypertrophy
Hypertrophic cardiomyopathy (HCM) is defined by the
presence of increased ventricular wall thickness or mass
without a loading condition such as hypertension or
valvular disease [7].
Cardiac amyloidosis
Cardiac amyloidosis describes amyloid deposition in the
heart, which may occur as part of systemic amyloidosis or
as a localized process.
Systemic amyloidosis (SAA) is a complication of chronic
inflammatory conditions, with renal disease being the
predominant feature, presenting with proteinuria and renal
failure.Cardiacinvolvementisrare[8]. Systemic amyloidosis
(SAL) is the most commonly diagnosed form of clinical
amyloid. Multiorgan involvement is common and the heart is
affected approximately 90% of the time. Diastolic heart
failure with right heart failure is the most common mode of
presentation [8]. Hereditary systemic amyloidosis is due to
deposition of amyloid fibrils derived from transthyretin,
lysosome or apolipoprotein A-1. Clinical syndromes include
cardiomyopathy, nephropathy or neuropathy. Senile systemic
amyloidosis iscausedby depositionofamyloid fibrils derived
from normal wild type transthyretin and presents as a slowly
progressive infiltrative amyloid cardiomyopathy [8].
CMR appearances
Cardiac amyloid typically demonstrates a diffuse decrease
in signal intensity on T1 weighted FSE images [9, 10]. It
generally causes diffuse hypertrophy of both the left and
right ventricles (Fig. 1a), in contradistinction to HCM,
which typically causes more focal hypertrophy. Thickening
of the interatrial septum (Fig. 1a) and posterior right atrial
wall >6 mm is also seen in cardiac amyloidosis [11]. Late
gadolinium enhancement (LGE) is another hallmark of
cardiac amyloidosis on CMR. In a study by Vogelsberg et
al. [12], LGE was demonstrated in 79% of patients with
cardiac amyloidosis. Several different patterns of LGE were
seen. There was LGE of the entire subendocardial circum-
ference, extending in various degrees into neighbouring
myocardium (Fig. 1b). Late gadolinium enhancement was
also distributed in large areas in the left ventricle, mainly
involving subendocardial areas circumferentially. Subepi-
cardial myocardium was typically less affected. Late
gadolinium enhancement in the papillary muscles was also
seen in approximately 40% of patients (Fig. 1b). Ejection
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Insights Imaging (2010) 1:293–308 295fractions, left ventricular end-diastolic volume and myocar-
dial mass were not significantly different between the
cardiac amyloid group and the other group of patients with
various cardiac disorders. The average interventricular
septum was 17 ± 4 mm in the amyloid group compared
with 13 ± 3 mm in the non-amyloid group [12]. A more
recent study by Syed et al. [13] of CMR appearances in 120
patients with cardiac amyloidosis demonstrated LGE in
97% of patients and increased left ventricular wall thickness
in 91%. Global transmural or subendocardial LGE was the
most common pattern seen in 83% of patients and this was
associated with greater interstitial amyloid deposition. In a
study of CMR appearances in 16 patients with amyloidosis,
a mild or moderate pericardial effusion was seen in 46% of
patients and a pleural effusion in 50% [14].
Friedreich’s ataxia
Friedreich’s ataxia is the most common of the hereditary
ataxia syndromes. Clinical features are secondary to a
reduction in fraxetin synthesis associated with an unstable
expansion of a GAA trinucleotide repeat [15]. Patients are
homozygous when a GAA expansion is present on two
alleles, irrespective of the length of the expansion, and
heterozygous when a GAA expansion is found on one
allele and a point mutation on the other allele [16]. The
clinical hallmark is progressive ataxia, generally starting
before 25 years of age, as well as dysarthria, sensory
neuropathy, lower limb areflexia, extensor plantar response
and weakness from degeneration of dorsal columns and
pyramidal tracts [17]. Skeletal abnormalities and glucose
intolerance are also present to a variable degree. Cardiac
involvement in Friedreich’s ataxia is a common finding and
is characterized by increased thickness of the ventricular
wall that is typically concentric and symmetrical, with a
normal or small LV cavity and normal systolic function
[18]. The age of disease onset and the rate of clinical
progression are variable and are influenced by the size of
the GAA expansion in the smaller allele (GAA1) [19].
CMR appearances
Rajagopalan et al. [19] demonstrated a correlation between
increasing GAA1 repeat numbers and increasing LV mass
(Fig. 2a, b). Left ventricular mass was higher in patients
with larger GAA1 (>600) repeat sizes. Left ventricle mass
positively correlated with the genetic severity of the disease
and is seen in earlier onset disease and short disease
duration. Longer disease duration is associated with smaller
LV mass. Septal and posterior wall thickness showed
similar changes with greater thickness seen in patient
groups with >600 GAA1 repeats [19]. The number of
patients with severe hypertrophy was relatively small and
overt hypertrophy relatively greater in patients with larger
GAA1 repeats [18, 20].
Noonan syndrome
Noonan syndrome is characterized by short stature, typical
faciesandcongenitalheartdefects.Noonansyndromeoccurs
in an autosomal dominant or sporadic inheritance. Male and
females are equally affected [21]. Its pathophysiology is not
fully understood. Four disease-causing genes have been
identified which are involved in the RAS/RAF/MEK/ERK
signal transduction pathway. These are PTPN11, SOS1,
RAF1 and KRAS [22, 23]. The cardinal features of Noonan
syndrome are unusual facies including hypertelorism,
down-slanting eyes, epicanthic folds, low-set posterior ears,
micrognathia and a webbed neck [24]. Short stature, chest
Fig. 1 A 78-year-old man who presented with progressive heart
failure. RV endomyocardial biopsy showed cardiac amyloid. a
Horizontal long axis SSFP sequence showed hypetrophy of the basal
segments of the LV (straight arrow), biatrial enlargement and
thickening of the interatrial septum (curved arrow). Note the small
pericardial effusion. b Late-enhanced sequence showed circumferen-
tial subendocardial high signal. Note the high signal on the RV side of
the interventricular septum resulting in the tram track sign (straight
arrow). Note also the small pericardial effusion (curved arrow)
296 Insights Imaging (2010) 1:293–308deformity, bleeding diathesis and mental retardation are
also cardinal features [25]. The phenotype becomes less
pronounced with increasing age [21].
CMR appearances
The most common cardiac defect is pulmonary valve
stenosis, which affects approximately 50% of patients with
Noonan syndrome [26]. Pulmonary stenosis is more
common in patients with PTPN11 mutations. Atrial septal
defects occur in approximately 10%, persistent ductus
arteriosus in 3% and ventricular septal defects in 5% [21].
Asymmetric septal hypertrophy is present in 20% of
patients (Fig. 3a, b)[ 27, 28]. A case report by Hudsmith
et al. [28] described the CMR appearances in a woman with
Noonan syndrome. The patient underwent open pulmonary
valvotomy and secundum atrial septal defect closure as a
child. There was asymmetrical septal hypertrophy detected
on CMR with an increased LV mass. Following gadolinium,
there was patchy increased signalinthe anterior,anteroseptal
and lateral walls. Myocardial hypertrophy associated with
Noonan syndrome is not strongly associated with sudden
death or rhythm disturbances though it is histologically
similar to non-syndromic HCM [26].
Danon disease
Danon disease is a multisystemic, lysosomal, glycogen-
storage disease with normal acid maltase [29]. It is
characterized by a triad of cardiomyopathy, skeletal
myopathy and variable mental retardation with intracyto-
plasmic vacuoles containing autophagic material and
glycogen in cardiac and skeletal muscle cells [30, 31].
Danon disease is an X-linked dominant disorder, though
spontaneous mutations have also been reported. Males are
Fig. 2 A 19-year-old man with Friedrichs ataxia who presented with
acute chest pain. a Short-axis SSFP sequence showed circumferential
hypertrophy of the left ventricle. b Late-enhanced sequence showed an
absence of high signal. Late-enhancement has not been described in FA
Fig. 3 A 46-year-old man with known Noonan’ss y n d r o m e .a
Horizontal long axis SSFP sequence showed septal hypertrophy
(arrow) and a dilated left atrium secondary to mitral regurgitation. b
Late-enhanced short axis sequence showed extensive high signal
involving the antero- and infero-septal myocardial segments (arrow)
Insights Imaging (2010) 1:293–308 297usually more severely affected than females and also
present at an earlier age. Age of presentation in males
ranges from infancy to the second decade and affected
males rarely survive beyond their 20 s and die secondary to
an arrhythmia or congestive cardiac failure [29]. Female
carriers develop cardiomyopathy during adulthood, most
commonly in the 4th or 5th decades. Both skeletal
myopathy and mental retardation are less common in
females [30]. Wolff-Parkinson-White, increased serum
creatinine kinase and ophthalmic abnormalities are also
seen in Danon disease [31, 32]. Mutations in the lysosome-
associated protein 2 (LAMP-2) have been identified as the
causative gene [31]. LAMP-2 is a heavily glycosated
protein found inside the lysosomal membrane. Its deficiency
results in excessive myocardial glycogen accumulation,
which is responsible for the myocardial hypertrophy [30].
CMR appearances
The glycogen storage disorders generally induce myocardial
hypertrophy. CMR is useful for assessing the severity of
hypertrophy and assessing function. Either concentric or
asymmetric hypertrophy is present in most male patients,
althoughsomepresent withlate-stagedilatedcardiomyopathy
(Fig. 4a, b). Female patients usually present with dilated
cardiomyopathy [33].
Piotrowska-Kownacka et al. [34] describe the CMR
appearances of a patient with Danon disease. Subendocar-
dial perfusion defects were visible in almost all segments
on first-pass perfusion sequences. These were located
predominantly in the lateral and anterior walls. Late
gadolinium enhancement was seen in the subendocardium
in the septal segments and transmurally in the anterior and
lateral walls.
Uncommon cardiomyopathies characterized by dilation
Dilated cardiomyopathies (DCM) are characterized by
dilatation of the cardiac chambers with impaired contraction
of the ventricles. DCM in the familial from is usually related
to cytoskeletal genetic mutations. Non-familial causes are
numerous and include myocarditis and drug causes.
Peripartum cardiomyopathy
Peripartum cardiomyopathy (PPCM) is a rare cause of heart
failure. It typically develops in the final month of pregnancy
or within 5 months of delivery. Its aetiology appears
multifactorial and complex. Several proposed theories for
its aetiology exist, including a form of viral myocarditis, an
abnormal immune response to pregnancy, an abnormal
response to hameodynamic stress of pregnancy, increased
myocyte apoptosis, cytokine–mediated myocardial inflam-
mation, malnutrition, genetic factors, excessive prolactin
production, abnormal hormone function and increased
adrenergic tone [35].
CMR appearances
Reports of the CMR appearances in PPCM show conflicting
results. Generally, patients present with a dilated left
ventricle (Fig. 5a, b). Results following the administration
of gadolinium are conflicting. Kawano et al. [36] described
a case of peripartum cardiomyopathy in which CMR at
2 months demonstrated diffuse epicardial and mid-wall late
gadolinium enhancement in the left ventricle. The late
gadolinium enhancement decreased on follow up CMR
performed at 10 months. Caballero-Borrego et al. [37]
described a case of PPCM imaged with CMR in the chronic
phase. CMR demonstrated extensive linear LGE at the
septal segments. In contrast, a case report by Leurent et al.
[38] in a patient with PPCM failed to show any LGE on
Fig. 4 A 21-year-old man with known Danon’s glycogen storage
disorder. a Short-axis SSFP sequence showed hypertrophy of the
interventricular septum (arrow). b Late-enhanced short axis sequence
showed circumferential high signal in the LV
298 Insights Imaging (2010) 1:293–308CMR 8 days after the onset of symptoms. A series of eight
patients by Mouquet et al. [39] evaluating the CMR
appearances in PPCM also failed to demonstrate myocar-
dial LGE, even in patients imaged within 2 weeks of
symptoms. No specific CMR characteristics were demon-
strated between the patients who regained LV function and
those who did not. Marmursztein et al. [40] described two
patients with PPCM imaged with CMR. One patient
demonstrated no CMR abnormality. The second patient
had several areas of myocardial LGE. At clinical follow-up,
the patient with a normal CMR had full recovery of cardiac
function and was asymptomatic. The patient with LGE on
CMR had persistent LV dysfunction.
This disparity in CMR reports is likely to be related to
the numerous causes of peripartum cardiomyopathy.
Baruteau et al. [41] divided peripartum cardiomyopathy
into two distinct subgroups: (1) non-inflammatory cardio-
myopathy secondary to malnutrition, genetics, excessive
prolactin production, abnormal hormone function and
increased adrenergic tone. The non-inflammatory cardio-
myopathies do not appear to cause late gadolinium
enhancement or T2 hypersignal; (2) inflammatory cardio-
myopathy are secondary to viral myocarditis, abnormal
immune responses in pregnancy, abnormal response to
hemodynamic stress, increased myocyte apoptosis and
cytokine-mediated inflammation. Inflammatory causes do
appear to cause late gadolinium enhancement on CMR.
Muscular dystrophy
Duchenne (DMD) and Becker (BMD) muscular dystrophies
are X-linked genetic disorders due to mutations in the
dystrophin gene. The protein dystrophin is totally absent or
dysfunctional in DMD and is reduced in expression or
mildlydysfunctionalinBMD.Duchennemusculardystrophy
is a more severe disorder and patients die of respiratory
failure, generally surviving only until the 3rd decade. In
contrast, BMD has a slower decline and patients may survive
until the 6th decade. Cardiomyopathy is the main cause of
death in BMD [42].
The incidence of cardiomyopathy in DMD is zero under
the age of 10 years, one-third at 14 years, half at 18 years
and 98% over 18 years [43].
CMR appearances
Early cardiac evaluation of patients with BMD and DMD is
required to assess those with early signs of cardiac
abnormalities who may benefit from early intervention.
Cardiac involvement in BMD begins at the subepicardium
of the inferolateral wall in the third decade of life and
increases in extent with age. Progressive myocardial
damage causes regional loss of contractility and a progres-
sive decrease in LV systolic function (Fig. 6a). Yilmaz et al.
[44] studied 15 patients with BMD. Twelve patients had
evidence of cardiac involvement by CMR. Patients with
reduced left ventricular ejection fraction were older, with
heavier hearts and regional wall motion abnormalities.
Late gadolinium enhancement was seen on CMR in
DMD involving predominantly the inferolateral free wall,
the basal inferior and anterolateral region of the left
ventricle (Fig. 6b). There was sparing of the right ventricle
and interventricular septum [45, 46]. Cardiac involvement
in BMD is uncommon under the age of 16 years,
increasing to approximately 70% by 40 years of age
[44, 47].
Drug related dilated cardiomyopathies
Myocarditis is an inflammatory disease of the myocardium
with a wide range of clinical presentations. It may be
Fig. 5 A 34-year-old woman with progressive shortness of breath
1 week following post-partum. a Short-axis SSFP sequence showed
mild dilation of the left ventricle (end-diastolic diameter=62 mm). b
Late-enhanced sequence showed an absence of high signal in this case
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immune disorders and drugs. It typically manifests in a
previously healthy person and may result in rapidly
progressive heart failure and arrhythmia. Acute myocarditis
with established ventricular dysfunction can progress to
dilated cardiomyopathy [48].
There are several case reports of ephedra-associated
myocarditis [49–51]. Ephedra is a potent sympathomimetic
agent with direct and indirect effects on adrenergic
receptors. An adverse effect of adrenergic stimulation is
myocyte toxicity [52]. Naik et al. [52] described two men,
aged 19 and 21 years respectively, who were admitted on
separate occasions with dilated cardiomyopathy secondary
to ephedra. Methamphetamine is a sympathomimetic agent
that causes sympathetic stimulation by excessive release of
noradrenaline and blockade of re-uptake at the sympathetic
synaptic receptors. Several case reports have documented
reversible dilated cardiomyopathy secondary to metham-
phetamine use [53, 54]. A case report by Lopez et al. [55]
evaluated the CMR appearances in a patient presenting with
cardiomyopathy secondary to methamphetamine. CMR
demonstrated a reduced ejection fraction of 37% but no
evidence of LGE, indicating no acute myocardial inflam-
mation. The patient improved following treatment and
repeat CMR showed improved ejection fraction to 64%.
In our institution, we have recently encountered a patient
with mephedrone-associated myocarditis. Mephedrone is a
cathinone derivative that is purchasable legally on the
Internet or in ‘head-shops’. This substance bears similar
pharmacological and structural similarities to amphetamine.
This is also referred to as ‘meow’, ‘meph’, ‘rush’ and ‘roxy’.
People presenting to hospital after taking mephedrone
describe a number of cardiovascular signs, agitation and
sometimes a drug-induced psychosis [56]. At least four
deaths in the UK in March 2010 and a further 18 deaths in
England and seven in Scotland have been attributed to
cathiniones [57].
CMR appearances
Drug–induced myocarditis CMR typically shows high
signal on T2-weighted sequences, an increased global
enhancement ratio and high signal on delayed enhanced
sequences (Fig. 7a and b). There is often regional wall
motion hypokinesis in the lateral segments. The abnormal
enhancement typically affects the lateral segments.
Uncommon cardiomyopathies characterized by restriction
Restrictivecardiomyopathiesdemsontrateventriculardiastolic
dysfunction, and typically bilateral atrial enlargement with
relativelynormalventricularend-diastolicvolumeandsystolic
function.
Systemic sclerosis
Systemic sclerosis (SSc) is a connective tissue disorder of
unknown aetiology characterized by diffuse vascular
lesions, fibrosis of the skin and other organs, including
the heart, kidneys and lungs. Excess collagen deposition is
a characteristic feature of systemic sclerosis. Systemic
sclerosis is divided into five forms: diffuse, limited,
transitory, systemic scleroderma sine scleroderma and
malignant scleroderma. The principal forms are diffuse
and limited systemic scleroses [58]. Diffuse systemic
sclerosis is characterised by Raynaud phenomenon that
precedes the development of skin changes by one year [59].
There is generalised skin fibrosis of the chest and limbs,
skin hyperpigmentation or hypopigmentation There is early
involvement of the lungs, kidneys, gastrointestinal tract and
Fig. 6 A 46-year-old man with progressive heart failure and known
Becker’s muscular dystrophy. a Short-axis SSFP sequence showed
dilation of the left ventricle (end-diastolic diameter=70 mm). b Late-
enhanced sequence showed extensive transmural high signal through-
out the lateral segments (arrows)
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sclerotic changes of the hands, feet, face and forearms.
There is telangictasia of the skin, cutaneous calcification
and late involvement of the lungs with late development of
pulmonary hypertension. Diffuse systemic sclerosis occurs
equally in males and females. Limited systemic sclerosis
has a female predominance. Sytemic scleroderma sine
scleroderma is characterised by involvement of the internal
organs alone with no external signs [58]. Diastolic
dysfunction may occur before any clinical sign or symptom
of the disease, in both diffuse and limited forms of the
disorder [60, 61].
CMR appeareances
Tzelepis et al. [62] reviewed the CMR appearances of 41
patients with SSc; 24 of 36 (66%) demonstrated LGE
characteristically midwall LGE with sparing of the sub-
endocardium (Fig. 8). There was a linear pattern in all
patients that was infrequently interrupted or spiculated. The
LGE predominantly involved the basal and mid ventricular
LV segments with less common involvement of the apices.
Patchy nodular enhancement was seen in the lower or upper
right ventricular insertion points in 17% of patients.
Myocardial fibrosis appears to progress from base to apex.
All patients with LGE had involvement of the basal
segments. Midcavity involvement was always associated
with basal involvement and apical involvement was
associated with basal and midcavity fibrosis. Apical
segment was seen in patients with a greater duration of
Raynaud’s phenomenon. Myocardial fibrosis was similar
between diffuse and localized SSc and was more severe in
patients with abnormal Holter results [62].
Hypereosinophilic syndrome
Idiopathic hypereosinophilicsyndrome (HES) is characterized
by peripheral eosinophilia and multiorgan dysfunction in the
absence of known causes of hypereosinophilia. The heart is
frequently involved and there are three stages of eosinophilia-
related cardiac damage. Stage one is an acute necrotic stage,
which is usually clinically silent. An intermediate stage
follows that is characterized by thrombus formation. This
leads to the third stage, which is a fibrotic stage resulting in
endomyocardial fibrosis and restrictive cardiomyopathy [63].
CMR appearances
Several case reports have documented the CMR appearances
of HES (Fig. 9a–c)[ 64–67]. Syed el al. [67] describe
Fig. 8 A 55-year-old man who presented with progressive shortness
of breath. He had a background history of severe systemic sclerosis.
Late-enhanced short-axis sequence showed extensive high signal in
the interventricular septum (arrows)
Fig. 7 A 21-year-old man admitted with severe central chest pain 12
h after orally ingesting mephedrone. a T2-weighted sequence showed
high signal in the lateral segments consistent with myocardial edema
(arrow). b Late-enhanced short-axis sequence showed high signal in
the mid-wall lateral segment consistent with acute myocardial
inflammation (arrow)
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obliteration of the LV cavity on systole. Following contrast,
a three-layered appearance on CMR was identified,
consisting of the normal uninfiltrated myocardium, a
hyperintense subendocardium and a linear hypointense
layer of thrombus found inside the endocardium. Similar
hyperenhancement of the endocardium compared with the
myocardium was seen on CMR by Salanitri [65].
Metastatic disease
Metastatic disease to the heart and pericardium is rare but is
more common than primary cardiac tumours [68]. Cardiac
metastases are associated with a poor prognosis. The most
common tumours to metastasize to the cardiac structures
are lung, lymphoma, breast, esophagus and melanoma [69,
70]. Bronchogenic carcinoma is the most common malig-
nancy to spread to the cardiac structures and adenocarci-
noma is the most common histological type [70]. Metastatic
disease from bronchogenic carcinoma to the heart may be
via direct spread, lymphatic or haematogenous spread.
Intrapericardial extension of tumour into the pericardium
and left atrium should be suspected when there is
obliteration of the superior pulmonary vein [71].
Involvement of the heart and pericardium is usually a
late manifestation of lymphoma. Cardiac involvement
occurs in 16% of patients with Hodgkin’s disease and
18% of patients with non-Hodgkin lymphoma. Metastases
are usually firm, focal nodules, which can be found in the
walls of all cardiac chambers and in the pericardium [72].
Breast cancer may spread via direct extension. Enhancement
of the pericardium or pericardial nodularity is suggestive but
not definitive of malignant involvement [73].
In melanoma, autopsy reports have shown myocardial
tissue replaced by extensive nodular deposits appearing as
pigmented epicardial ‘black’ implants. This black macro-
scopic appearance gave rise to the term ‘charcoal heart’ [74].
CMR appearances
Most cardiac tumours are low signal intensity on T1
sequences and brighter on T2 sequences (Fig. 10a, b)
[75]. Malignant disease enhances post contrast administra-
tion (Fig. 10c). A case reported by Rathi et al. [76]
described the CMR appearances of ‘charcoal heart’. There
was nodularity of the LV myocardium with varying
penetration into the endocardium and epicardium. On SSFP
cine sequences, the nodular deposits were isointense to
bright when compared with normal myocardium. There
were also multiple mass-like deposits lining the right atrial
and left atrial wall with similar imaging signal charac-
teristics to the LV myocardium. These nodular deposits
were high signal on both T1 and T2 sequences. Masses
Fig. 9 A 38-year-old man with hypereosinophilic syndrome presented
with progressive shortness of breath. Serum measurements showed a
white cell count of 45,000, 41,000 of which were eosinophils. a
Horizontal long-axis SSFP sequence showed mild circumferential
hypertrophy of the left ventricle. b Late-enhanced short-axis sequence
showed extensive high signal in the interventricular septum and lateral
wall. c Late-enhanced horizontal long-axis view confirms extensive
high signal throughout the septum and lateral basal segments (arrows)
302 Insights Imaging (2010) 1:293–308with high melanin content are hyperintense on T1 sequences
due to shortening of the T1 relaxation time. Hyperintensity
on T2 reflects high increased proton density or water content
of the tumour. A case report by Deetjen et al. [77] described
a cardiac metastasis from a renal cell adenocarcinoma,
which also demonstrated a nodular enhancing mass. There
was heterogeneous signal in the nodular mass on T1 and T2
sequences. Osteogenic sarcoma involving the heart is rare
but merits mention as the metastasis contains bone. These
calcific areas of increased opacity may be visible on chest
X-ray but are better characterized on CT. Calcification is
shown as a signal void on CMR.
Cardiomyopathies that are unclassified
This group of unclassified cardiomyopathies includes left
ventricular noncompation and Takotsubo cardiomyopathy.
Left ventricular non-compaction
Left ventricular non-compaction (LVNC) is a myocardial
disorder characterized by prominent and excessive trabecu-
lations and deep intratrabecular recesses. These recesses
communicate with the ventricular cavity rather than the
coronary circulation [78]. Chin et al. [79] were the first
group to use the term LVNC in their review of eight cases
in 1990. Left ventricular non-compaction is postulated to
arise from an abnormality of the normal myocardial
maturation process. The early fetal myocardium has deep
recesses between loosely interwoven fibres, which commu-
nicate with the ventricular cavity. The trabeculations
provide oxygenation exchange by creating a larger surface
for direct exchange diffusion from the cardiac lumen. In the
5th–8th weeks of fetal life, the coronary circulation
develops. obviating the need for direct exchange transfu-
sion and in a normal fetus the loosely interwoven fibres
undergo compaction [80]. The severity of LVNC will
depend on the timing of the arrest in the myocardial
maturation and compaction process. Compaction moves
from base to apex, from epicardium to endocardium and
from the septal to the lateral wall. This process of
maturation explains why the apex and midventricular lateral
segments are more commonly involved in LVNC [81].
Histology demonstrates that ventricular endothelium lines
the recesses and is in continuity with the ventricular cavity
[82]. Other histopathological characteristics include focal
ischemic necrosis within the trabeculations and endocardial
layer, compensatory hypertrophy of the myocardium,
interstitial fibrosis and scarring reflecting focal replacement
fibrosis [83].
Familial LVNC can be transmitted as an autosomal
dominanttraitwithincompletepenetranceandlesscommonly
as an autosomal recessive trait and X-linked inheritance are
Fig. 10 A 46-year-old man with progressive shortness of breath. He
was diagnosed with HIV and endomyocardial biopsy revealed cardiac
lymphoma. Echocardiography suggested diastolic heart failure. a
Short-axis SSFP sequence showed circumferential infiltration of the
basalsegmentsoftherightandleftventricle.b Pre-contrast T1-weighted
horizontal long-axis sequence showed extensive lymphomatous infil-
tration of all four heart chambers. c Post-contrast T1-weighted
horizontal long-axis sequence showed marked enhancement of the
extensive lymphomatous infiltrating masses throughout the heart
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seen in a minority of patients with LVNC [80, 84]. Non-
compaction has been reported in association with neuromus-
cular disorders including Barth syndrome (also G4.5 genetic
mutation), muscular and myotonic dystrophies, Pompe’s
disease, mitochondrial and various other genetic disorders [85].
It is also seen in association with other congenital cardiac
defects, ventricular septal defects being the most frequent.
Further congenital defects include subaortic obstruction,
bicuspid aortic valves, coarctation of the aorta, Ebstein’s
anomaly, valvular pulmonary stenosis, Tetralogy of Fallot and
pulmonary atresia [86, 87].
LVNC can present as fetal hydrops, neonatal heart
failure and with ventricular fibrillation in its most severe
form [80]. Cardiac failure is the most prevalent finding and
complication in all studies of LVNC [78, 88]. Arrhythmias
and thromboembolic events are more common in the adult
population. In the study by Oechslin et al. [78], 11
thromboembolic events were seen in eight patients (24%),
one stroke, six episodes of transient ischaemic attacks, one
mesenteric infarction and three episodes of pulmonary
embolism. Ventricular tachycardia were seen in 14 patients
(41%).
CMR appearances
Echocardiography has previously been the mainstay imaging
modality in the diagnosis of LVNC. Diagnostic criteria for
LVNC on echocardiography have become confusing, some
studies suggesting using a two layered myocardium with a
non–compacted to compacted ratio of more than 2:1 (end
systolic value) and colour Doppler flow within the trabecu-
lations [89]. Other studies suggest using more than two
thickened trabeculations as a diagnostic criteria.
CMR is increasingly performed for confirmation of the
diagnosis and also to evaluate for complications related to
the disorder. It has the advantage over echocardiography of
optimal apical and lateral wall visualization, which are the
most commonly involved segments [90]. Appearances can
be variable with three basic features described by Dursun et
al. [89]; extensive spongiform transformation of the left
ventricular myocardium, trabeculations of the ventricular
wall with deep recesses of the ventricular cavity and a
dysplastic appearance of the myocardium with thinned
myocardium and excessive trabeculations.
The end diastolic non-compacted to compacted ratio
(NC/C) is higher in patients with LVNC (Fig. 11a). A
compactionratio canbe quantitatively assessed by measuring
thickness in millimeters of the noncompacted to the com-
pacted myocardium. This can be done on a myocardial
segmental basis using the standard 17-segment cardiac AHA
model [91]. The NC/C parameter is able to distinguish
pathological noncompaction from lesser forms of non-
Fig. 11 A 38-year-old woman with progressive shortness of breath. a
Vertical long-axis SSFP sequence showed increased trabeculations at
the apical ventricular level. (arrow) b Short-axis SSFP sequence
showing the importance of precise image planes when evaluating
LVNC. Radial image planes with the placed through the centrepoint of
the LV cavity avoids the risk of prescribing oblique planes. c Late-
enhanced vertical long-axis sequence showed high signal throughout
the trabeculae consistent with trabecular fibrosis (arrow)
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sequences, and use high-resolution thin slices to do so (4-
5 mm). It is also useful to utilise radial slice projections,
with the fulcrum passing through the centre of the LV
(Fig. 11b). In this way, the risk of measuring the NC/C ratio
from an oblique slice is minimised. The diastolic ratio of
>2.3 on CMR demonstrates high diagnostic accuracy in
identifying pathological LVNC and is now widely regarded
as the gold-standard.
Fibrosis may be observed in LVNC on CMR, which
correlates with histological findings (Fig. 11c). Delayed
enhancement is usually found in a subendocardial distribu-
tion. Delayed enhancement can also be found in some
compacted normal segments indicating that fibrosis is also
present in these normal appearing areas [89].
Takotsubo cardiomyopathy
Takotsubo cardiomyopathy (TTC) is also referred to as
apical ballooning syndrome and stress cardiomyopathy. It
was first described in Japan almost twenty years ago [92].
The diagnosis is based upon transient akinesia or dyskinesia
of the LVapical, mid or basal segments extending beyond a
single coronary vascular distribution; absence of angio-
graphic evidence of acute plaque rupture or obstructive
coronary artery disease; new ECG abnormalities or elevated
troponin; no recent head trauma, intracranial bleeding,
hypertrophic cardiomyopathy or phaeochromocytoma
[93]. Takotsubo may also be accompanied by acute chest
pain that when accompanied with ECG changes and cardiac
enzyme rises explains why many patients are initially
misdiagnosed with acute coronary syndrome.
ThepathogenesisbehindTTChasnotbeenfullyelucidated.
Coronary spasm, coronary emboli with spontaneous fibrino-
lysis, abnormalitiesin the coronarymicrovascularfunction and
regional myocarditis are some suggestedetiologies.Numerous
studies have linked it with catecholamine excess [94, 95]. One
study described TTC in nine patients immediately following
intravenous administration of epinephrine or dobutamine
[95]. Both emotional and physical stresses are commonly
seen as a precursor to TTC. Plasma catecholamine and
neuropeptidelevelsinpatientswithTTCinducedbyemotional
stress are markedly elevated compared with patients with
myocardial infarction [94]. Endocardial biopsies of patients
with TTC support excessive catecholamine exposure charac-
terized by contraction bands, increased interstitial fibrosis and
regional accumulation of inflammatory cells [96].
CMR appearances
The imaging appearances of TTC are currently evolving.
Cine SSFP sequences in vertical long axis and short axis
views allow the optimal assessment of left ventricular
Fig. 12 A 54-year-old woman admitted with acute onset chest pain
following a road traffic accident. Vertical long-axis SSFP sequence in
(a) diastole and (b) systole showed akinesis of LV myocardial
segments at the midventricular level. The basal and apical segments
showed vigorous contraction. (c) Late-enhanced short-axis sequence
showed an absence of scar, excluding significant infarction
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Several patterns of regional wall motion abnormalities have
been described [95]. (1) Apical ballooning variant, which is
characterized by apical akinesis with sparing of the base;
(2) midventricular ballooning variant with midventricular
akinesis with sparing of the apex and base (Fig. 12a, b); (3)
basal ballooning variant with midventricular and basal
akinesis with normal apical contractility. Right ventricular
akinesia can also be seen in some patients. In this subgroup,
it has been suggested that such patients may also have
lower LV ejection fractions [97].
Eitel et al. [98] have highlighted the discriminating
ability of CMR in patients presenting with acute chest pain
syndromes. Late gadolinium enhancement (LGE) was seen
in patients with myocardial infarctions and myocarditis, but
not in patients with TTC (Fig. 12c). One study has
demonstrated LGE in patients with TTC, though the LGE
was of lower signal intensity than seen in myocardial
infarction or myocarditis and the extent of tissue involve-
ment was minimal [99].
Eitel et al. [98] evaluated a large group of patients
presenting with TTC. Several interesting findings were
described. Of 136 patients with TTC, 121 had significant
stressful events 12 h preceding their TTC. Sixty-four
patients had emotional stress and 57 had a physical stress.
As with all other studies of TTC, post-menopausal women
were more commonly affected, but 10% of patients were
pre-menopausal, 10% were male and 10% did not recover
LV function immediately [97].
Conclusion
CMR is an excellent imaging modality for the evaluation of
the rare and unclassified cardiomyopathy. It allows the
detection, morphology, function and myocardial contrast-
enhancement characteristics of these cardiomyopathy to be
accurately and reproducibly analysed.
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